Company History

Company History

From a small tissue bank at the University of Florida to a global surgical implant company with four world-class manufacturing facilities, RTI Surgical (RTI) has a history of innovation.

Tutoplast® Tissue Sterilization Process developed

January 1969

The Tutoplast Tissue Sterilization Process was developed to sterilize and preserve tissue for implantation. The Tutoplast Process inactivates pathogens and removes bacteria, and the low dose gamma irradiation ensures sterility of the final packaged product.

Pioneer® Surgical Technology Formed

May 1992

Dr. Matthew Songer, an orthopedic surgeon, founded Pioneer in 1992 in Marquette, MI. Songer was not satisfied with the spinal cables on the market, which encouraged him to develop his own, a product we still distribute, called the Songer® Spinal Cable.

Tutogen Medical® formed

October 1992

In October 1992, Tutogen Medical (Tutogen) forms and builds its headquarters in Neunkirchen am Brand, Germany. Tutogen manufactures safe, high-quality xenograft and allograft implants for use in surgeries around the globe.

Precision tooled allograft introduced

January 1996

The first allograft to be precision tooled, a threaded cortical dowel, was introduced by University of Florida Tissue Bank.

Tutogen expands to Florida

January 1998

Tutogen expands to the United States by moving its corporate headquarters to Progress Park in Alachua, Fla.

Regeneration Technologies, Inc. begins operations

February 1998

RTI began operations as Regeneration Technologies in Alachua, Fla. In February 1998, the University of Florida Tissue Bank transferred its allograft processing operations, related equipment and technologies, distribution arrangements, and research and development activities to Regeneration Technologies. This spin off from the University of Florida (UF) is one of the most successful UF technology transfers to date.

BioCleanse® Tissue Sterilization Process developed

March 2000

In March 2000, RTI made history in the allograft industry by developing its patented BioCleanse Sterilization Process. The BioCleanse Process is a low-temperature chemical sterilization process that inactivates or removes bacteria, fungi, spores and viruses from tissue without compromising the tissue’s biocompatibility or structural integrity.

RTI listed on NASDAQ®

August 2000

RTI completed an initial public offering in August 2000 and began trading on the NASDAQ stock exchange under the symbol RTIX.

Assembled Implant Patent

August 2002

US Patent for assembled bone implants issued on August 6, 2002.

Regeneration Technologies merges with Tutogen to form RTI Biologics®

February 2008

In February 2008, Regeneration Technologies became a global company after merging with Tutogen, creating RTI Biologics, Inc. Both companies were located in Progress Park in Alachua, Fla. Following the merger, RTI became one of the leading providers of sterile biologic implants for surgeries, offering surgeons both allograft and xenograft implants.

RTI Biologics acquires Pioneer Surgical Technology to form RTI Surgical®

July 2013

RTI acquired Marquette, Mich.-based Pioneer® Surgical Technology, Inc., a global manufacturer of metal and synthetic implants, becoming RTI Surgical. In July 2013, the acquisition resulted in an expanded product portfolio. Today, RTI provides surgeons with safe biologic, metal and synthetic-based implants.

RTI Surgical® Names Camille Farhat Chief Executive Officer

January 2017

RTI announced that Camille Farhat had been named Chief Executive Officer. Mr. Farhat’s expertise aligned with RTI’s focus on developing and delivering exceptional products for patients and achieving sustainable, long-term growth. He has a track record of revitalizing and profitably growing global businesses within the health care industry.

RTI Surgical® Introduces TETRAfuse® 3D Technology

October 2017

RTI announced the introduction of TETRAfuse® 3D Technology, an interbody fusion (IBF) device material, manufactured under an exclusive license with Oxford Performance Materials, designed to help drive optimal outcomes for patients undergoing spinal fusion procedures. It is the first 3D printed polymer-based IBF device material to incorporate a nano-rough surface that has demonstrated, in a pre-clinical study, more notable trabecular bone ingrowth compared to PEEK and titanium-coated PEEK.

RTI Surgical® Announces Acquisition of Zyga Technology, Inc.

January 2018

RTI signed an agreement to acquire Zyga Technology, Inc., a leading spine-focused medical device company that develops and produces innovative minimally invasive devices to treat underserved conditions of the lumbar spine. Zyga Technology’s primary product is the SImmetry® Sacroiliac Joint Fusion System.

RTI celebrates 20-year anniversary of providing safe, high-quality surgical implants

April 2018

RTI celebrated a significant global milestone of providing more than 8 million biologic implants processed through RTI’s proprietary sterilization processes with zero confirmed incidence of implant-associated infection.

RTI Surgical® and Aziyo® Biologics Announce Exclusive Agreement to Distribute ViBone®

August 2018

ViBone is a bone repair product designed to perform and handle more closely to autograft in a variety of orthopedic procedures. ViBone is processed using a proprietary method optimized to protect and preserve the health of native bone cells to potentially enhance new bone formation. Together, RTI and Aziyo will initiate new research on ViBone to build on the characterization and other data currently available.

RTI Surgical Wins 2018 Orthopedics This Week Spine Technology Award

September 2018

RTI announced its TETRAfuse® 3D Technology won a 2018 Spine Technology Award from Orthopedics This Week, a widely read publication in the orthopedics industry. “RTI is honored to receive this important industry recognition, which is a testament to the ingenuity and dedication of our employees,” said Camille Farhat, President and CEO, RTI Surgical.

RTI Surgical Completes Acquisition of Paradigm Spine

March 2019

RTI completed the acquisition of Paradigm Spine, LLC, a leader in motion preservation and non-fusion spinal implant technology. Paradigm Spine’s primary product is the coflex® Interlaminar Stabilization® device.